Mutational inactivation of the RB1 tumor suppressor gene initiates retinoblastoma and other human cancers. RB1 protein (pRb) restrains cell proliferation by binding E2f transcription factors and repressing the expression of cell cycle target genes. It is presumed that loss of pRb/E2f interaction accounts for tumor initiation, but this has not been directly tested. RB1 mutation is a late event in other human cancers, suggesting a role in tumor progression as well as initiation. It is currently unknown whether RB1 mutation drives tumor progression and, if so, whether loss of pRb/E2f interaction is responsible. We have characterized tumorigenesis in mice expressing a mutant pRb that is specifically deficient in binding E2f. In endocrine tissue, the mutant pRb has no detectable effect on tumorigenesis. In contrast, it significantly delays progression to invasive and lethal prostate cancer. Tumor delay is associated with induction of a senescence response. We conclude that the pRb/E2f interaction is critical for preventing tumor initiation, but that pRb can use additional context-dependent mechanisms to restrain tumor progression.
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retinoblastoma gene | cellular senescence | mouse model M utation of the RB1 tumor suppressor gene initiates the onset of human retinoblastoma and other human cancers (1) . Similarly, Rb1 mutation in mice can initiate lethal tumorigenesis, typically with alterations in other genes like Trp53 (2-8).
The best characterized mechanism underlying Rb1 protein (pRb) function is its physical interaction with E2f transcription factors (9, 10) . When bound to E2fs, pRb blocks their ability to activate transcription and recruits repressive chromatin-modifying factors to actively silence gene expression (11) . E2f target genes include those important for the cell cycle (12) , and E2f activity is necessary for cell proliferation (13) . Such observations have led to the hypothesis that pRb suppresses tumor initiation by binding E2f and blocking the elaboration of an E2f-dependent transcriptional program that drives cells to proliferate. This hypothesis has not been directly tested by specific disruption of the pRb/E2f interaction. RB1 mutation occurs late in the progression of other human cancers like prostate cancer (14) (15) (16) (17) , suggesting loss of RB1 may also drive progression of previously initiated neoplasia. As current mouse models cannot distinguish between effects of Rb1 loss on tumor initiation from possible effects on tumor progression, in vivo experimental evidence supporting this possibility is lacking.
To address these issues, we created a mutant Rb1 allele in the mouse encoding pRb specifically deficient for E2f binding (18) . The mutant allele (Rb1 654 ) encodes an arginine-to-tryptophan substitution at codon 654, a position within a hydrogen bond network specifying the structure of the pRb/E2f interaction surface (19) . The amino acid substitution compromises E2f binding, but does not affect binding to other known pRb binding partners (18, 20, 21 ). An analogous germ line mutation has been identified in human hereditary retinoblastoma. Tumorigenesis associated with this mutation is characterized by reduced penetrance and expressivity (22) . We have tested the tumor suppressor activity of this mutant Rb1 allele in pituitary, thyroid, and prostate tissue.
Results

Spontaneous Endocrine Tumorigenesis Is Similar in Rb1
−/+ and Rb1 −/+ mice completely lacked pRb ( Fig. 1 B and C) . As pRb 654 expression had no detectable effect on endocrine tumorigenesis, disruption of the pRb/E2f interaction was apparently sufficient to initiate tumorigenesis. However, it remained possible that the R654W mutation disrupts additional functions beyond pRb/E2F interaction. If disruption of pRb/E2F interaction was the primary defect causing tumor initiation in Rb1 654/+ mice, then reducing E2f activity should lower the incidence of lethal endocrine tumors as previously demonstrated in Rb1 −/+ mice (27) . Loss of E2f1 increased the survival of both Rb1 −/+ and Rb1 654/+ mice to a similar extent, with at least 80% of mice surviving to 600 d (Fig. 1A ). As pRb 654 had no detectable tumor suppressor activity and tumorigenesis was rescued by compound E2f1 loss, disruption of the pRb/E2f interaction and deregulation of E2f activity was the primary driver of tumor initiation in the affected tissues. mice are embryonic lethal (18) , precluding analysis of adult mice. However, prostate tissue can be rescued from Rb1 null embryonic urogenital sinus tissue by subrenal transplantation (28) . Rescued Rb1 −/− prostate tissue is prone to hormone-induced carcinogenesis (29) . Urogenital sinus transplanted from Rb1 654/− embryos is also able to differentiate into prostate tissue (Fig. S1 ), and we have compared the susceptibility of Rb1 −/− and Rb1 654/− rescued prostate tissue to hormone-induced carcinogenesis. The majority of prostate epithelium in rescued grafts is normal, with localized regions of epithelial hyperplasia in about 75% of cases. Rb1 status does not affect the incidence of hyperplasia. Eight weeks of testosterone plus estradiol (T+E2) treatment increases the incidence of hyperplasia to 100% of grafts for all genotypes and also increases the extent of hyperplasia. Consistent with previous reports, mouse prostatic intraepithelial neoplasia (mPIN) is observed in 83% of treated Rb1 −/− grafts, but not in wild-type grafts. In contrast, mPIN lesions are present in only 13% of treated Rb1 654/− grafts ( Table 1) . Similar results are observed upon extending T+E2 treatment to 16 wk, the maximum length of treatment due to ensuing tissue atrophy.
To assess possible effects of Rb1-deficient mesenchyme on carcinogenesis, we have analyzed E+T2-induced carcinogenesis in grafts generated by recombining urogenital sinus tissue with wild-type rat urogenital mesenchyme. In recombined grafts, the stromal component of the rescued tissue is composed primarily of wild-type rat cells, whereas prostate epithelium is of mouse origin (28 prostate epithelium in sensitivity to T+E2-induced carcinogenesis remains. The data suggest pRb 654 is able to suppress progression of hormone-induced hyperplasia to neoplasia.
The length of these experiments is limited, thus it is unclear whether mPIN lesions will progress to carcinoma. To bypass this limitation, we tested pRb 654 tumor suppressor activity in an autochthonous mouse model of prostate cancer. Prostate-specific deletion of Rb1 and Trp53 causes metastatic carcinoma with neuroendocrine features (7, 30 − mice, and tumors first develop from mPIN-like precursor lesions in the periurethral proximal prostate (30) . We have graded the histopathology of prostate tissue from a cohort of mice at 14 through 22 wk of age to determine whether pRb 654 affects early preneoplastic or mPIN lesions. Both Rb1 654 and Rb1 − mice exhibit focal cellular atypia and mPIN lesions with comparable frequency at 16 wk ( Table 2 ). The histology of mPIN arising in mice of both genotypes is similar (Fig. S3B) . The mPIN lesions progress to invasive carcinoma in about 25% of Rb1 − mice at 16 wk, increasing to about 60% by 22 wk. Despite the similar incidence of focal cellular atypia and mPIN, no invasive carcinoma is detected in Rb1 654 mice by 22 wk. We have examined older mice (n = 10 per genotype), and no carcinoma is detected in Rb1 654 mice as old as 26 wk of age. These findings indicate that pRb 654 does not prevent initiation of preneoplastic and early neoplastic lesions, but does slow progression to invasive prostate carcinoma. (Fig. S4) . Under optimal culture conditions, no consistent difference in proliferation of PrE cultures was observed that correlated with Rb1 status (Fig. S5) . We did note that wild type or pRb 654 expressing PrE plated at low density exhibited cells with an enlarged and flattened morphology reminiscent of cellular senescence.
To explore this finding, we assayed senescence-associated β-galactosidase activity (SA-bgal) in PrE cultures subjected to senescence-inducing stresses. PrE rescued from Rb1 +/+ or Rb1 654/654 embryos showed a significant percentage of SA-bgal positive cells when treated with H 2 O 2 or when cultured without serum ( Fig. 3 A and B) Proximal prostate tissue from age-matched mice of the indicated genotype was dissected, and H&E stained sections throughout the entire gland at 50-μM intervals were examined. Each mouse was scored with the most advanced lesion detected. The fraction of mice with the indicated histopathology is shown. (Fig. 3C) . 3D ). These observations demonstrated that PrE expressing pRb or pRb 654 were capable of undergoing a senescence response to H 2 O 2 treatment or serum deprivation, whereas PrE completely lacking pRb were not.
The ability of pRb 654 -expressing PrE to undergo senescence in vitro suggests the possibility that it also retains senescenceassociated functions in vivo. To test this, we analyzed sections from both rescued and native prostate tissue for evidence of senescence. Little or no detectable SA-bgal staining was observed in proximal prostatic ducts from wild-type or Rb1 − mice, but SAbgal staining was observed in some ducts from Rb1 654 mice (Fig.  4A) . Primary prostate tumors from Rb1 654 mice also showed rare SA-bgal positive cells, but SA-bgal staining was not detectable in tumors from Rb1 − mice (Fig. 4B) . SA-bgal staining was also observed in T+E2-treated prostate tissue rescued from Rb1 +/+ or Rb1 654/− embryos, but not from Rb1 −/− embryos (Fig. 4C ). Another marker of cellular senescence is expression of the cyclin-dependent kinase inhibitor p16INK4a (p16). Immunostaining of tissue sections for p16 indicated that most cells within proximal mPIN lesions from 18-to 22-wk-old Rb1 654 mice were positive for p16. In contrast, few cells within Rb1 − mPIN lesions showed detectable p16 staining (Fig. 5A) . Consistent with induction of senescence, the fraction of proliferating cells was significantly lower in proximal mPIN lesions from Rb1 654 mice compared with Rb1 − mice (Fig. 5B ). Primary and metastatic tumors from Rb1 654 mice also had a lower fraction of proliferating cells, although these smaller differences did not reach statistical significance. We also noted significant p16 staining in foci of atypical, preneoplastic cells in distal prostate epithelium from Rb1 654 mice, whereas similar atypical cells from Rb1 − mice lacked detectable p16 staining (Fig. 5C ).
Regulation of E2f Target Genes in Prostate Tissue. Whereas pRb 654 is deficient in binding E2f in PrE (Fig. S6) microarray data for some of these relevant E2F target genes (Fig. 6) . Thus we find no evidence that pRb 654 is able to repress the expression of E2f cell cycle or senescence-associated target genes.
Discussion
The importance of the pRb/E2f interaction for regulating gene expression and the cell cycle has been established by over two decades of research (34) . It is assumed that this interaction mediates pRb tumor suppressor activity, yet this has not been directly tested in vivo. To fill this gap, we have characterized the tumor suppressor activity of pRb 654 , a mutant deficient in binding E2f. PRb 654 has no detectable tumor suppressor activity in endocrine tissue. Further, compound loss of E2f1 significantly reduces the incidence of endocrine tumors in pRb 654 -expressing mice. These data provide direct in vivo evidence implicating disruption of the pRb/E2f interaction as the primary molecular defect causing tumor initiation in the affected tissues.
Surprisingly, pRb 654 retains detectable tumor suppressor activity in two mouse models of prostate cancer. In both models, pRb 654 fails to prevent initiation of preneoplastic or early neoplastic lesions. This is consistent with the R654W mutation fully disrupting the ability of pRb to prevent tumor initiation. However, the progression of these early lesions to invasive carcinoma and lethal disease is markedly slowed by pRb 654 . We conclude that the R654W mutation does not fully disrupt the ability of pRb to restrain prostate tumor progression. Whether all Rb1 654 mice would eventually die from prostate cancer cannot be unequivocally determined as they succumb to pituitary and thyroid tumors beginning at ≈40 wk of age. These endocrine tumors arise at a rate similar to those in Rb1 −/+ or Rb1 654/+ mice, or Rb1 654/F :Trp53 F/F mice lacking the cre transgene. Thus tumorigenesis is initiated by spontaneous loss of the floxed wild-type Rb1 allele rather than cre-mediated recombination. This observation highlights within individual mice the difference in Rb1 654 tumor suppressor activity in different tissues. This observation supports the emerging hypothesis that pRb uses multiple, context-dependent mechanisms to suppress tumorigenesis.
In both mouse models, suppression of prostate tumor progression by pRb 654 is associated with cellular senescence. PrE expressing pRb 654 or wild-type pRb, but not PrE lacking pRb, are also capable of undergoing senescence in vitro. The requirement for pRb in PrE senescence is in contrast to previous observations in murine fibroblasts and may be due to lack of compensatory upregulation of p107 or p130 in pRb null PrE (Fig. S7) . Deregulated E2f activity is a known trigger of cellular senescence (35) , and pRb is known to be important for enforcing the senescence response (36 The best characterized mechanism contributing to pRbmediated cellular senescence involves pRb/E2f interaction and repression of E2f target genes (33, 37) . However, we find no evidence that pRb 654 is able to repress E2f cell cycle or senescenceassociated target genes. We conclude that functions beyond pRb/ E2F contribute to the senescence-associated suppression of tumor progression observed. Additional study will be required to identify these mechanisms. We note that despite continued expression of pRb 654 , advanced and metastatic prostate tumors from Rb1 654 mice exhibit less cellular senescence than early lesions. Whatever the mechanisms responsible, evolving tumors have a means to bypass or abrogate them in a way that does not depend on loss of the Rb1 654 allele. The genetics of human retinoblastoma demonstrate that Rb1 loss plays an important role in tumor initiation. The results presented here support the hypothesis that disruption of the pRb/E2f interaction and deregulation of E2f activity is the primary molecular defect driving tumor initiation in the context of Rb1 mutation. In some human cancers, however, pRb loss occurs only at later stages of disease. A significant unresolved question is whether pRb loss drives the progression of previously initiated neoplasia and, if so, whether disruption of the pRb/E2f mechanism is responsible. By genetically separating pRb-mediated effects on tumor initiation from effects on tumor progression, the R654W Rb1 allele provides direct in vivo experimental evidence implicating Rb1 loss as a driver of tumor progression in addition to its effects on tumor initiation. Although the data do not address whether disruption of pRb/E2f affects tumor progression, they do suggest that additional mechanisms beyond pRb/E2f contribute to the ability of pRb to restrain tumor progression and suppress tumorigenesis. The observed pRb-mediated effects on tumor progression are tissue specific. Thus the impact of Rb1 alteration on tumorigenesis is context dependent, varying both on the type of defect and the cell where it occurs. This has important implications for our understanding of how pRb deficiency contributes to cancer. A more thorough appreciation of the variety of molecular mechanisms contributing to pRb-mediated tumor suppression will advance efforts to use this important regulatory network for the diagnosis and treatment of cancer.
Materials and Methods
Mice. Derivation and genotyping of mice have been previously described (7, 18, 23) . Experimental mice are on a mixed C57BL/6, 129/SVJae, and FVB genetic background. For survival analysis, mice were monitored daily, euthanized when moribund, and necropsy performed to verify cancer diagnosis. Survival analysis using the Kaplan-Meier method was performed with SPSS version 17. All animal work was performed under Roswell Park Cancer Institute or Vanderbilt University Medical Center institutional animal care and use committee approved protocols.
Tissue Rescue and Isolation of PrE Cultures. Prostate tissue rescue and recombination using urogenital sinus tissue from embryos at 13 d of gestation were performed as previously described (29) . Hormone treatment was by implantation of Silastic capsules filled with 25 mg of testosterone and 5 mg of 17β-estradiol (Sigma) at the time of grafting.
For isolation of prostate epithelial cell cultures, tissue grafts or native tissue dissected from the proximal prostate of 60-d-old mice were minced and plated onto collagen-coated culture dishes in DMEM (BioWhittaker) supplemented with 2.5% charcoal stripped FCS, 5 μg/mL of insulin/transferring/ selenium (Collaborative Research), 10 μg/mL of bovine pituitary extract (Sigma), 10 μg/mL of epidermal growth factor (Collaborative Research), 1 μg/ mL of cholera toxin (Sigma), 100 U/mL of penicillin G and streptomycin Fig. 6 . E2f target gene expression in prostate tissue. RNA was extracted from prostate tissue of the indicated genotype and the expression levels of the indicated genes determined by quantitative RT-PCR. The data represent the fold change in expression relative to a wild-type prostate tissue reference sample, normalized to β-actin RNA levels. The mean and SD of data from two mice for each genotype, each performed in triplicate, are shown. The asterisk marks a statistically significant difference between genotypes (Student's t test, P < 0.05).
(BioWhittaker). Two weeks later, areas of epithelial cells were dissected and digested with collagenase, trypsinized, and replated. Epithelial cells were further purified from remaining fibroblasts as described (38) . Senescence experiments were performed using a senescence detection kit (Calbiochem). For BrdU-labeling experiments, cultured cells were treated with 1.0 or 2.0 mM of H 2 O 2 for 24 h with equivalent results, allowed to recover for 2 d, pulse labeled with BrdU for 3 h, and then fixed and stained using a cell proliferation assay kit as recommended (GE Healthcare).
Histology and Immunostaining. Prostate tissue was fixed in 10% neutral buffered formalin or phosphate-buffered 4% paraformaldehyde, paraffin embedded, and serially sectioned at 5-μm thickness through the entire specimen. Every 10th section was H&E stained for assessment of histopathology. Pathology was verified by a pathologist (M.W.) and a veterinary pathologist (A.Y.N.). Primary antibodies used for immunostaining were antiserine 10 phosphorylated histone H3 (Upstate) and p16Ink4A (Santa Cruz Biotechnology). Stain was developed using biotinylated goat anti-rabbit secondary antibody and the ABC reagent as recommended (Vector Laboratories). For senescence associated β-galactosidase staining, tissue specimens were embedded in OCT and cryosections prepared at 5-μm depth. Sections were fixed and stained as recommended using a senescence detection kit (Calbiochem).
RNA and Protein Analysis. RNA was extracted from prostate tissue using the RNeasy method (Qiagen). RNA was reversed transcribed for PCR amplification and DNA sequencing using the SuperScript first-strand synthesis system (Invitrogen). The Rb1 PCR primers used were 5′-GTGTAAATTCTGCTGCAAAT-3′ and 5′-GGTCCAAATGTCGGTCTCTC-3′. Two-color gene expression profiling, using 44K whole mouse genome oligo microarrays (Agilent Technologies), was performed as previously described (39) . Prostate tissue RNA from two Rb1 654 mice or two age-matched Rb1 − mice was individually profiled against prostate RNA pooled from three wild-type mice. The microarray data have been deposited in the GEO repository, accession no. GSE25615. Quantitative RT-PCR was performed using the Brilliant II 1-step high ROX master mix (Agilent Technologies). The 5′ nuclease quantitative PCR assays (Integrated DNA Technologies) were run using an ABI 7300 real-time PCR machine. Relative expression was calculated with Sequence Detection software, version 1.4, using the ddCt method. The endogenous control was β-actin. The sequences of quantitative PCR primers and probes are available upon request. Protein was extracted from tissue or cultured cells and analyzed by Western blotting as previously described (40) . Blots were stained with primary antibodies against pRb (Pharmingen) or Hsp70 (Stressgen).
